Singapore markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
691.69-0.13 (-0.02%)
As of 03:44PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
31/12/2018
Total revenue
14,226,800
16,071,700
8,497,100
7,863,400
6,710,800
Cost of revenue
2,137,800
2,437,500
1,119,900
782,200
434,100
Gross profit
12,089,000
13,634,200
7,377,200
7,081,200
6,276,700
Operating expenses
Research development
3,089,100
2,908,100
2,735,000
3,036,600
2,186,100
Selling general and administrative
1,930,900
1,824,900
1,346,000
1,834,800
1,556,200
Total operating expenses
5,008,600
4,687,400
3,800,600
4,871,400
3,742,300
Operating income or loss
7,080,400
8,946,800
3,576,600
2,209,800
2,534,400
Interest expense
55,000
57,300
56,900
30,200
28,200
Total other income/expenses net
-681,100
436,300
290,700
249,500
47,300
Income before tax
6,344,300
9,325,800
3,810,400
2,429,100
2,553,500
Income tax expense
657,500
1,250,500
297,200
313,300
109,100
Income from continuing operations
5,686,800
8,075,300
3,513,200
2,115,800
2,444,400
Net income
5,686,800
8,075,300
3,513,200
2,115,800
2,444,400
Net income available to common shareholders
5,686,800
8,075,300
3,513,200
2,115,800
2,444,400
Basic EPS
-
76.40
32.65
19.38
22.65
Diluted EPS
-
71.97
30.52
18.46
21.29
Basic average shares
-
105,700
107,600
109,200
107,900
Diluted average shares
-
112,200
115,100
114,600
114,800
EBITDA
-
9,669,300
4,103,200
2,669,600
2,729,900